News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
849,592 Results
Type
Article (86631)
Company Profile (703)
Press Release (762256)
Multimedia
Podcasts (135)
Webinars (17)
Section
Business (232738)
Career Advice (4129)
Deals (39732)
Drug Delivery (129)
Drug Development (91022)
Employer Resources (198)
FDA (18136)
Job Trends (17348)
News (396602)
Policy (39777)
Tag
Academia (3002)
Academic (2)
Accelerated approval (7)
Adcomms (32)
Allergies (97)
Alliances (56895)
ALS (109)
Alzheimer's disease (1528)
Antibody-drug conjugate (ADC) (173)
Approvals (18086)
Artificial intelligence (356)
Autoimmune disease (32)
Automation (17)
Bankruptcy (405)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (121)
Biotechnology (481)
Bladder cancer (91)
Brain cancer (34)
Breast cancer (343)
Cancer (2703)
Cardiovascular disease (225)
Career advice (3536)
Career pathing (34)
CAR-T (193)
Cell therapy (535)
Cervical cancer (22)
Clinical research (73747)
Collaboration (985)
Company closure (3)
Compensation (606)
Complete response letters (30)
COVID-19 (2889)
CRISPR (58)
C-suite (296)
Cystic fibrosis (113)
Data (2639)
Decentralized trials (2)
Denatured (47)
Depression (60)
Diabetes (319)
Diagnostics (6948)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (49)
Drug discovery (162)
Drug pricing (144)
Drug shortages (34)
Duchenne muscular dystrophy (115)
Earnings (97392)
Editorial (47)
Employer branding (25)
Employer resources (168)
Events (130906)
Executive appointments (846)
FDA (19673)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (897)
Gene editing (135)
Generative AI (36)
Gene therapy (401)
GLP-1 (876)
Government (5195)
Grass and pollen (6)
Guidances (179)
Healthcare (20902)
Huntington's disease (27)
IgA nephropathy (33)
Immunology and inflammation (163)
Immuno-oncology (3)
Indications (32)
Infectious disease (3057)
Inflammatory bowel disease (160)
Inflation Reduction Act (12)
Influenza (62)
Intellectual property (110)
Interviews (813)
IPO (17865)
IRA (52)
Job creations (5191)
Job search strategy (2861)
Kidney cancer (13)
Labor market (50)
Layoffs (576)
Leadership (25)
Legal (10124)
Liver cancer (82)
Lung cancer (386)
Lymphoma (185)
Machine learning (9)
Management (65)
Manufacturing (394)
MASH (90)
Medical device (14669)
Medtech (14674)
Mergers & acquisitions (22494)
Metabolic disorders (851)
Multiple sclerosis (99)
NASH (23)
Neurodegenerative disease (127)
Neuropsychiatric disorders (37)
Neuroscience (2199)
NextGen: Class of 2025 (7685)
Non-profit (5086)
Now hiring (44)
Obesity (449)
Opinion (281)
Ovarian cancer (88)
Pain (108)
Pancreatic cancer (96)
Parkinson's disease (178)
Partnered (25)
Patents (275)
Patient recruitment (131)
Peanut (52)
People (65477)
Pharmaceutical (143)
Pharmacy benefit managers (24)
Phase I (22766)
Phase II (32034)
Phase III (24105)
Pipeline (1561)
Policy (199)
Postmarket research (3552)
Preclinical (10285)
Press Release (72)
Prostate cancer (128)
Psychedelics (39)
Radiopharmaceuticals (275)
Rare diseases (471)
Real estate (7396)
Recruiting (75)
Regulatory (26920)
Reports (61)
Research institute (2663)
Resumes & cover letters (649)
Rett syndrome (8)
RNA editing (9)
RSV (51)
Schizophrenia (88)
Series A (155)
Series B (105)
Service/supplier (30)
Sickle cell disease (61)
Special edition (21)
Spinal muscular atrophy (166)
Sponsored (35)
Startups (4297)
State (2)
Stomach cancer (16)
Supply chain (78)
Tariffs (61)
The Weekly (86)
Vaccines (845)
Venture capitalists (48)
Weight loss (310)
Women's health (44)
Worklife (20)
Date
Today (110)
Last 7 days (633)
Last 30 days (3624)
Last 365 days (35139)
2025 (15131)
2024 (38139)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1271)
Alabama (66)
Alaska (7)
Arizona (275)
Arkansas (14)
Asia (50296)
Australia (8848)
California (7184)
Canada (2237)
China (627)
Colorado (308)
Connecticut (323)
Delaware (179)
Europe (115427)
Florida (1052)
Georgia (246)
Hawaii (1)
Idaho (65)
Illinois (688)
India (31)
Indiana (361)
Iowa (15)
Japan (197)
Kansas (115)
Kentucky (30)
Louisiana (16)
Maine (72)
Maryland (1038)
Massachusetts (5498)
Michigan (262)
Minnesota (453)
Mississippi (3)
Missouri (94)
Montana (32)
Nebraska (26)
Nevada (76)
New Hampshire (72)
New Jersey (2002)
New Mexico (31)
New York (2020)
North Carolina (1194)
North Dakota (10)
Northern California (3101)
Ohio (237)
Oklahoma (16)
Oregon (48)
Pennsylvania (1550)
Puerto Rico (17)
Rhode Island (38)
South America (1653)
South Carolina (31)
South Dakota (1)
Southern California (2646)
Tennessee (118)
Texas (1080)
United States (27247)
Utah (210)
Virginia (193)
Washington D.C. (77)
Washington State (647)
West Virginia (4)
Wisconsin (80)
There are 849,592 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval
Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified a potential accelerated approval pathway. The company has pared down its staff to conserve resources to fund a potential resubmission.
May 30, 2025
·
2 min read
·
Angela Gabriel
Layoff Tracker
iTeos Winding Down Operations
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
May 30, 2025
·
215 min read
·
BioSpace Editorial Staff
Immunology and inflammation
Sanofi, Regeneron Shares Tumble as Dupixent Follow-Up Fails Phase III COPD Test
Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their blockbuster Dupixent in the I&I space, was “contrary to our expectations—we were wrong.”
May 30, 2025
·
3 min read
·
Annalee Armstrong
Lung Cancer
Summit’s Bispecific Misses Survival Endpoint in Global Phase III Trial but Analysts Remain Optimistic
Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient populations.
May 30, 2025
·
3 min read
·
Nick Paul Taylor
Pharma Industry in Crisis: How to Preserve Quality While Balancing Budget and Time in Today’s Financial Climate
With venture funding tightening in the post-COVID landscape, efficiency has become more critical than ever. In this interactive webinar industry experts will explore actionable strategies for maintaining quality under financial pressure.
May 30, 2025
Press Releases
Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi
May 30, 2025
·
2 min read
Press Releases
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
May 30, 2025
·
4 min read
Press Releases
Ascend Aesthetic Partners Welcomes David Cutter as COO
May 30, 2025
·
2 min read
Press Releases
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
May 30, 2025
·
16 min read
Press Releases
Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research
May 30, 2025
·
5 min read
1 of 84,960
Next
